Loading…
← CockpitCompetitor Analysis › 1795.TW Lotus Pharmaceutical Co., Ltd.Open in the cockpit ↗

Lotus Pharmaceutical Co., Ltd.1795.TWCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Major

Taiwan-based generic and specialty drugmaker focused on CNS, oncology and other therapeutic generics, with global licensing deals.

≈ A Taiwanese Teva, smaller scaleMomentum laggard 11
Mkt cap
$921M
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$8.90M
20-day average traded
Fwd P/E
9.8×
forward earnings
ROIC−WACC
+1.9 pp
WACC 5.0%
Hurdle
-18 pp
Req g minus delivered
Next earnings
120 days
18 Mar 2027
Close · TWDNT$121.50
1D-3.6%
1W-22.1%
1M-32.9%
3M-31.8%
6M-37.0%
YTD-57.1%
1Y-57.7%
ATR %5.9%
52w lowhigh67.1% off high

What Lotus Pharmaceutical does

Taiwan-based generic and specialty drugmaker focused on CNS, oncology and other therapeutic generics, with global licensing deals.

Sells generic drugs in Taiwan and Asia and in the US through marketing partners, while its approved plants also make drugs under contract for other companies. Licensing tie-ups with partners such as Japan's Kaken bring upfront and milestone payments on top of product sales.

In one line: A Taiwanese Teva, smaller scale.

Products and services

  • Generic pharmaceuticals
  • Licensed specialty drugs (CNS, oncology)
  • Contract manufacturing

Customers

  • Hospitals and pharmacies (Taiwan, Asia, US via par
  • Licensing partners (e.g., Kaken Pharmaceutical)

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Generic/specialty drug manufacturing

What could go right

  • US generic drug approvals
  • Licensing deals with Japanese/global partners

What could go wrong

  • Generic price erosion
  • Regulatory/FDA inspection risk

Moat: narrow (regulatory licence, process know-how). US FDA/Japan-approved plants and licensing tie-ups give access generics rivals lack.

Headquarters: Taipei, Taiwan · Employees: 1,585

Named competitors

Lotus Pharmaceutical at a glance

Size Lotus Pharmaceutical (1795.TW) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $921M, the 277th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$121.50 on 18 Nov 2026.

Performance Over six months the shares fell 37.0%, against -20.9% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th lowest of 20 in its peer set.

Growth Revenue grew 66.6% over the last twelve months (peer median +2.4%); the operating margin is 21.4% (peer median 7.1%).

Valuation It trades at 9.8× forward earnings against a peer median of 24.4× (cheapest of 9).

Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -18 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.9 points above its cost of capital (5.0% WACC).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 811795.TW 65
Six months, rebased to 100: Lotus Pharmaceutical against the median of its 20 peers (local-currency closes).

Lotus Pharmaceutical financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$31.1BNT$20.5BNT$18.6BNT$17.0BNT$14.6B
Revenue growth—+10%+10%+16%—
Gross profitNT$14.1BNT$10.6BNT$9.86BNT$8.34BNT$7.02B
EBITDANT$9.04BNT$7.44BNT$7.30BNT$6.11BNT$5.05B
Net incomeNT$2.22BNT$4.72BNT$5.07BNT$4.11BNT$3.02B
Free cash flowNT$2.32BNT$6.18BNT$5.81BNT$1.21BNT$3.16B
Capital expenditureNT$5.01BNT$4.35BNT$1.47BNT$3.28BNT$3.07B
Total debtNT$59.0BNT$55.9BNT$13.7BNT$11.6BNT$8.92B

Quarterly statements and history in the cockpit →

Lotus Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-25%0%+25%300401039200MLTXIMTX6881772595600252688553600422002437603538AKTS20053002946887594565SANOFICONR1795.TW6-month return →1-month return →
Up and to the right = strong over both horizons. Lotus Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%20×40×300401039200603538STAR20053002944565SANOFICONR1795.TWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lotus Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%+30%0%20%300401039200600252688553002437603538STAR00059720054565SANOFICONR1795.TWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Lotus Pharmaceutical is the large dot.

Lotus Pharmaceutical competitors and peer comparison

Head to head with its named competitors (1795.TW vs 1789.TW vs ZYDUSLIFE.NS vs SDZ.SW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Lotus Pharmaceutical 1795.TW$921M-37%+67%21%9.8×-3.7%
Scinopharm Taiwan 1789.TW$435M-2%-5%-4%39.4×2.1%
Zydus Lifesciences ZYDUSLIFE.NS$12.8B+18%+24%17%30.0×n/a
Sandoz SDZ.SW$41.7B+26%+1%15%24.5×7.5%

How Lotus Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lotus Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure1795.TWPeer medianRank in peer set
1-month return-32.9%-9.1%2nd lowest of 21
6-month return-37.0%-20.9%5th lowest of 20
Distance from 52-week high-67.1%-46.6%2nd lowest of 21
Revenue growth (TTM)+66.6%+2.4%3rd highest of 18
Operating margin21.4%7.1%4th highest of 18
Forward P/E9.8×24.4×cheapest of 9
Growth the price implies (Req g, 7 yrs)-3.7%10.3%3rd least demanding of 12
Growth delivered (Del g)+13.8%+4.9%4th highest of 12
Hurdle (Req g minus delivered)-17.5 pp+2.8 pp2nd least demanding of 12
ROIC minus cost of capital+1.9 pp-2.0 pp5th highest of 15
EV / EBITDA9.1×12.5×cheapest of 6
Net debt / EBITDA5.7×1.8×most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%9.8×-3.7%+13.8%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%22.9×9.1%+13.4%
Oscotec 039200.KSSouth Korea$923M-32%+510%59%50.2×-10.2%+18.1%
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Immatics IMTXUnited States$913M-46%-44%-589%n/an/an/a
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%n/an/an/a
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%n/an/an/a
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%n/a10.3%-13.7%
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%n/a19.4%-6.0%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%n/an/an/a
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%n/a7.7%-6.9%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%42.3×11.6%+4.9%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%15.9×17.6%+7.8%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%n/an/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%n/a-7.6%-0.7%
SSY 2005.HKHong Kong$948M+8%-4%12%12.5×2.3%-0.5%
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%21.4×n/an/a
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
Nxera Pharma 4565.TJapan$974M+46%+24%14%25.8×17.7%+27.3%
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%28.1×17.7%+22.7%

Questions

Who are Lotus Pharmaceutical's main competitors?
Named competitors: Standard Chem & Pharm (private or unlisted), Scinopharm Taiwan (1789.TW), Zydus Lifesciences (ZYDUSLIFE.NS), Sandoz (SDZ.SW). The cockpit's measured peer set (industry) also includes Zhejiang Garden Biopharmaceutical (300401.SZ), Oscotec (039200.KS), MoonLake Immunotherapeutics (MLTX), Immatics (IMTX), Bio-Thera Solutions (688177.SS), Genfleet Therapeutics (Shanghai) (2595.HK).
Is Lotus Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 9.8× against a peer median of 24.4×, cheapest of 9 in its peer set. For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -18 pp: the price already allows for a slowdown.
How has Lotus Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -37.0% against -20.9% for the median peer; over one year -57.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.